Official websites use .gov
A
.gov
website belongs to an official government organization in the
United States.
Secure .gov websites use HTTPS
A
lock
(
) or
https://
means you’ve safely connected to the .gov website. Share sensitive
information only on official, secure websites.
Study Design: Observational
Conditions: Diabetes Mellitus, Diabetes Mellitus, Type 1
Division: DEM
Available Genotype Data: No
Image Summary: No
Transplant Type: None
Does it have dialysis patients: No
Access to biospecimens for Long-Term Investigative Follow-Up in TrialNet Study (TN16) is currently only available via collaboration. Please contact the parent study to ask about ancillary study opportunities.
Study Website: https://trialnet.org/our-research/long-term-follow-up
Data Package Version Number: 2 (Updated on: June 9, 2022)
DOI: 10.58020/w3gs-0421
How to cite this dataset: Krischer, Jeffrey (2023). Long-Term Investigative Follow-Up in TrialNet Study (V2) [Dataset]. NIDDK Central Repository. https://doi.org/10.58020/w3gs-0421
Data availability statement: Data from the Long-Term Investigative Follow-Up in TrialNet Study [(V2)/https://doi.org/10.58020/w3gs-0421] reported here are available for request at the NIDDK Central Repository (NIDDK-CR) website, Resources for Research (R4R), https://repository.niddk.nih.gov/.
The LIFT Study is available nationwide to TrialNet participants who either:
Developed diabetes while being monitored in the Pathway to Prevention Study or during participation in any prevention trial. The purpose is to study people early in the disease process
Participated in any new onset studies. The purpose is to learn more about diabetes and if there are any long-term effects—good or bad—from the treatments used in these studies
Participants will be asked to return to a TrialNet site annually or semi- annually, based on their ongoing ability to produce insulin. Visits will include metabolic testing (i.e., Oral Glucose Tolerance Test and/or Mixed Meal Tolerance Test), HbAc1, and possibly other blood or urine tests.
To study subjects early in the Type 1 Diabetes process, and to study if there are any long-term effects from the treatments used in previous new onset studies.
Inclusion Criteria:
Subjects that were previously enrolled in a TrialNet study for people newly diagnosed with type 1 diabetes
Subjects that developed type 1 diabetes while participating in the Pathway to Prevention Study or a TrialNet prevention study.
This study is ongoing.
Specimens and Study Datasets
| Plasma | 13546 |
| PB-PBMC | 9306 |
| Serum | 4881 |
| Whole Blood | 2996 |
| Forms |
 |
Manual_of_Operations (PDF) - 1.7 MB | |
| |
Protocol (PDF) - 549.8 KB | |
| |
TN16_Data_Challenge_Data_Dictionary_V1 (PDF) - 213.1 KB | |
| |
TN16_Data_Dictionary_V2 (PDF) - 246.8 KB | |
| |
TN16_Data_Dictionary_V2_Screen_Reader_Version (PDF) - 158.8 KB | |
| |
TN16_DSIC (PDF) - 136.4 KB | |
| |
TN16_Roadmap_V2 (PDF) - 148.9 KB |
Documents made accessible specifically for screen readers are marked with the eye icon . Other accessible documents are marked with the person icon .
If you need accessible versions of documents without an icon, please email your request to NIDDK-CRsupport@niddk.nih.gov.
